 to show improvements from a regulatory standpoint with the FDA over the current therapy. Also, we need an endpoint that would be indicative of long-term outcomes. As Dr. Newell indicated, will that kidney continue to function for many years post-transplant, and so that they can promote those advantages of their new therapy over the current standard of care.